A Phase Ib, Blinded, Randomized, Multicenter, Multiple-Ascending−Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UTTR1147A Administered by Subcutaneous Injection in Patients With Non-Healing Neuropathic Diabetic Foot Ulcers

Trial Profile

A Phase Ib, Blinded, Randomized, Multicenter, Multiple-Ascending−Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UTTR1147A Administered by Subcutaneous Injection in Patients With Non-Healing Neuropathic Diabetic Foot Ulcers

Recruiting
Phase of Trial: Phase I

Latest Information Update: 01 Aug 2017

At a glance

  • Drugs RG 7880 (Primary)
  • Indications Diabetic foot ulcer
  • Focus Adverse reactions
  • Sponsors Genentech
  • Most Recent Events

    • 26 Jul 2017 Planned End Date changed from 1 Nov 2017 to 21 May 2018.
    • 26 Jul 2017 Planned primary completion date changed from 1 Nov 2017 to 21 May 2018.
    • 20 Jul 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top